Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Focus Asia.
Press releases published on September 28, 2025
Racent(NicSRS) to Host Launch and Demo Event for sslTrus CLM on Oct 28th, with Cohost Sectigo
To tackle the challenge of 47-day SSL, Racent(NicSRS) will present a live demo and QA for its award-winning sslTrus CLM (certificate lifecyle manager) on Oct 28 HONG KONG, HONG KONG, September 29, 2025 /EINPresswire.com/ -- Racent(NicSRS) will host a …
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
1. About LEQEMBI (generic name: lecanemab, Chinese brand name: 乐意保) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble …
Arctic Valtrix: Why Traders Are Backing This AI Trading Platform for Security and ROI – Read Canada Arctic Valtrix Report!
New York City, NY, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Introduction – What is Arctic Valtrix Arctic Valtrix is positioned as a next-generation financial technology platform that integrates algorithmic intelligence, automation, and enhanced security to …
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a …
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab
VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program using the higher clinical response level of HS Clinical …
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reduction (p<0.0001) - The …